Medical Use and Dosing Regimen Patents in Canada
Medical use patents protect new uses and dosing regimens of drugs. In Pharmascience v. Janssen, 2026 SCC 26, the Supreme Court confirmed that methods of medical treatment are not patentable, but upheld specific dosing regimens that do not depend on physicians' professional skill and judgment.

Key takeaways
- Pharmascience v. Janssen, 2026 SCC 26, confirms methods of medical treatment are not patentable in Canada.
- The test asks whether the invention itself depends on professional medical skill and judgment.
- Treatments tailored to individual patients are more likely to be unpatentable methods.
- Specific dosing regimens that tell physicians how to administer a drug can be valid.
- New uses of known compounds remain patentable, but do not support a CSP.
Medical use patents in Canada after Pharmascience v. Janssen
Medical use patents are valuable life-cycle assets for pharmaceutical companies, and in July 2026 the Supreme Court of Canada clarified their limits. In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26 (17 July 2026), the Court confirmed that methods of medical treatment cannot be patented in Canada because they would monopolize professional medical skill and judgment. But it upheld Janssen's patent on specific dosing regimens for an injectable schizophrenia drug, because the claimed regimens told physicians how to administer the drug rather than requiring them to exercise professional judgment. The decision gives patentees a workable test and gives generics a clear line of attack, and it will shape how medical use patents are drafted, licensed and litigated in Canada for years.

This article explains the methods-of-medical-treatment exclusion, the Supreme Court's guidance, how claims to new uses, dosage forms and dosing regimens fare after the decision, and how to draft and enforce medical use patents in Canada, including in PM(NOC) litigation. Read the Court's summary in its Case in Brief.
The methods-of-medical-treatment exclusion
The Patent Act does not expressly exclude methods of medical treatment. The exclusion comes from case law, starting with the Supreme Court's decision in Tennessee Eastman Co. v. Commissioner of Patents, [1974] S.C.R. 111, which held that a method of surgical bonding was not patentable.
Later cases built a line of authority holding that claims requiring the skill and judgment of a physician, such as claims to choose a dose for a particular patient within a range, were invalid. At the same time, since Shell Oil Co. v. Commissioner of Patents, [1982] 2 S.C.R. 536, a new use of a known compound can be patented, which made "use" claims the standard vehicle for second medical use inventions in Canada.
The tension between these lines of authority produced years of uncertainty, particularly for dosing regimen claims, which can look like instructions to doctors. Courts sometimes upheld fixed-dose claims and sometimes struck down claims that left dosing to the physician. Pharmascience v. Janssen is the Supreme Court's first full treatment of the issue in decades.
What the Supreme Court decided
Facts
Janssen developed an injectable drug for schizophrenia and, through research and trials, dosing regimens designed to achieve optimal drug concentrations in patients. It obtained a patent in 2016 that set out, among other things, specific dosing regimens. In 2020, Pharmascience sought approval of a generic version, and Janssen sued for infringement in the Federal Court. Pharmascience argued that the patent was invalid because it claimed methods of medical treatment. The Federal Court upheld the patent and the Federal Court of Appeal dismissed the appeal.
Holding
The Supreme Court dismissed Pharmascience's appeal. Writing for the majority, Justice Jamal held that methods of medical treatment are not patentable under Canadian law because professional skills are not patentable, and that a patent focused on a method of medical treatment is invalid. He offered three general observations to guide the analysis:
- Courts should focus on whether the invention itself depends on professional medical skill and judgment, not on whether skill and judgment are applied in deciding whether to use the invention.
- The more a treatment must be tailored to individual patients, the more likely it is to be a method of medical treatment.
- The more medical professionals would be expected to develop or improve the subject matter of an invention, the more likely it is to be a method of medical treatment.
These observations are not exhaustive and do not replace a case-by-case analysis. Applying them, the Court held that Janssen's specific dosing regimens did not require a physician's professional skill and judgment: physicians still decide whether the treatment is appropriate for a patient, but the patent tells them how the regimen is to be administered. Two justices concurred in the result with separate reasons.
A physician's decision to prescribe does not make a claim a method of medical treatment. The question is whether the claimed invention itself requires the physician to exercise judgment, for example by titrating, choosing a dose from a range or adjusting to individual response. Fixed, specified regimens are on the safer side of the line.
Why the decision matters for businesses
For innovators, the decision ends a period in which the validity of medical use patents claiming dosing regimens depended heavily on which line of lower-court authority a judge followed. A patentee can now point to a structured analysis focused on the invention itself. Dosing research that produces a defined regimen, supported by pharmacokinetic and clinical data, can support a valid patent even though physicians still decide whether to prescribe the drug.
For generic and biosimilar manufacturers, the decision narrows one invalidity argument but sharpens it. Claims that require individual titration, dose selection within a range or adjustment based on patient response remain vulnerable, and the second and third observations give generics evidence-based ways to argue that a claimed regimen is the kind of thing clinicians develop themselves. For investors and acquirers, the decision changes the valuation of portfolios that rely on dosing and new-use claims: some patents that looked fragile before July 2026 are now more robust, and some broad claims may look weaker.
How Canada compares internationally
Canada's approach differs from its major trading partners. In Europe, methods of treatment of the human body are excluded from patentability, but second and further medical uses of known substances can be claimed as purpose-limited product claims, and dosing regimens can support such claims. In the United States, methods of treatment are patentable, subject to the general requirements of patent law. Canada sits between the two: methods of medical treatment are excluded, but use claims and defined dosing regimens can be valid. Companies filing internationally should adapt claim sets for Canada rather than relying on European or US claims, which may be in a format that is invalid or difficult to enforce here.
How different medical use patents fare
| Claim type | Position after 2026 SCC 26 (indicative) | Key risk |
|---|---|---|
| Compound or composition | Patentable subject matter | Novelty and obviousness |
| Use of a compound to treat a disease ("Swiss-style" or use claims) | Generally permissible since Shell Oil | Must not require professional judgment to practise |
| Fixed dosing regimen (specified dose, route and schedule) | Can be valid where the regimen is set by the claim | Obviousness over prior dosing studies |
| Dose ranges requiring selection for each patient | Higher risk of being a method of medical treatment | Claims tailored to individual patients |
| Dosage form (tablet, injectable formulation) | Patentable as a product | Prior art formulations |
| Surgical or therapeutic procedures performed by clinicians | Generally excluded | Methods-of-medical-treatment exclusion |
Drafting medical use patents after Pharmascience
The decision rewards claims that define the invention concretely. Practical drafting points include:
- Specify the regimen. Claim specific doses, routes, timing and sequences where the invention lies in the regimen, rather than leaving choices to the clinician.
- Use product and use formats. Include claims to the dosage form, kit or packaged product, and use claims, so that protection does not depend on a single format.
- Avoid titration language such as "adjusting the dose based on patient response" in independent claims; place it, if needed, in dependent claims.
- Explain the research. Describe how the regimen was developed, including pharmacokinetic modelling and trial data, to support utility and non-obviousness and to show that the invention is not something physicians would routinely develop.
- Think about infringement. Use claims are infringed by those who make or sell for the claimed use; consider how the generic's product monograph and labelling will be compared with the claims.
Applicants with pending applications should review their claims in light of the three observations, and patentees with granted patents should assess whether dependent claims provide fallback positions against an invalidity attack. See our page on patents.
Questions the decision leaves open
Several issues will be developed in later cases. First, how much flexibility a claim can leave to the clinician before it becomes a method of medical treatment: a regimen that allows a choice between two fixed doses based on a simple criterion, such as body weight or kidney function, sits closer to the line than a single fixed regimen.
Second, how the third observation applies to regimens developed through clinical trials in which physicians participate: evidence about who would ordinarily develop such improvements will matter. Third, how the analysis applies to diagnostic and companion-diagnostic methods, personalized medicine and digital therapeutics, where treatment is tailored by design. Patentees and challengers should expect expert evidence on clinical practice to become more important in each of these areas.
Medical use patents in PM(NOC) and infringement litigation
Medical use and dosing regimen patents are frequently listed on the patent register under the PM(NOC) Regulations, which permit listing of patents with claims for the use of the medicinal ingredient where that use has been approved. They are therefore regularly litigated in section 6 actions. After Pharmascience v. Janssen, invalidity arguments based on the methods-of-medical-treatment exclusion will focus on the three observations, and expert evidence on how physicians actually use the regimen will be central. Generics will also continue to rely on obviousness, since dosing improvements are often said to be routine optimization, and patentees should be ready with evidence of the research effort and unexpected results behind the claimed regimen.
Infringement of use claims raises its own issues. A generic that "skinny labels" its product to omit a patented use may still face inducement arguments if its product monograph or marketing encourages the patented use. See our insight on section 6 actions and our page on IP litigation.
Medical use patents and product life cycle strategy
Medical use patents often extend protection beyond the compound patent, but they protect less: generics can usually launch for unpatented indications or with different dosing. Their value therefore depends on how much of the market the patented use represents. They also interact with other tools. A new use of an already-approved ingredient will not support a certificate of supplementary protection, since CSPs require a first authorization for the medicinal ingredient; data protection and pricing rules also apply. See our insights on certificates of supplementary protection and PMPRB guidelines, and our life sciences and health page.
How TRW & Co helps
We advise pharmaceutical innovators, generic and biosimilar manufacturers and investors on medical use patents in Canada. We review claims in light of Pharmascience v. Janssen, develop life-cycle and listing strategies, assess validity and infringement risk, and support PM(NOC) and infringement litigation alongside Canadian-licensed litigation counsel and registered patent agents. We also advise on licensing and acquisitions involving pharmaceutical patent portfolios. To discuss a patent, a claim set or a product launch, contact us. This article is general information, not legal advice.
Frequently asked questions
Are dosing regimen patents valid in Canada?
They can be. In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, the Supreme Court upheld a patent on specific dosing regimens because the claimed regimens told physicians how to administer the drug and did not require professional skill and judgment. Claims that leave dosing choices to the physician remain at risk.
Why are methods of medical treatment not patentable?
The Supreme Court held that professional skills are not patentable, so a patent that focuses on a method of medical treatment would effectively monopolize physicians' professional skill and judgment. The exclusion comes from case law, not from an express provision of the Patent Act.
What factors decide whether a claim is a method of medical treatment?
The Court offered three observations: focus on whether the invention itself depends on professional judgment; the more treatment is tailored to individual patients, the more likely it is a method of treatment; and the more professionals would be expected to develop or improve the subject matter, the more likely it is excluded.
Can a new use of a known drug be patented?
Yes. Since Shell Oil (1982), new uses of known compounds can be patented in Canada, typically through use claims. The claims must still avoid requiring professional medical judgment and must be new and non-obvious.
Can medical use patents be listed under the PM(NOC) Regulations?
Yes, if the patent contains a claim for the use of the medicinal ingredient and that use has been approved in the relevant drug submission. Use patents are therefore often litigated in section 6 actions against generic manufacturers.
Sources
General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.


